Search

Boston Scientific Corp.

Închisă

SectorSănătate

51.81 0.12

Rezumat

Modificarea prețului

24h

Curent

Minim

51.68

Maxim

52.75

Indicatori cheie

By Trading Economics

Venit

-437M

904M

Vânzări

239M

5.4B

P/E

Medie Sector

19.945

57.002

EPS

0.86

Marjă de profit

16.612

Angajați

59,000

EBITDA

-214M

1.4B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+20.41% upside

Dividende

By Acuity

Următoarele câștiguri

28 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

5.5B

73B

Deschiderea anterioară

51.69

Închiderea anterioară

51.81

Sentimentul știrilor

By Acuity

41%

59%

144 / 340 Clasament în Healthcare

Boston Scientific Corp. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 aug. 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market trading, continuing a trend of six consecutive sessions finishing higher. No specific news was identified.

13 aug. 2026, 23:01 UTC

Social Media

Boston Scientific shares are higher in after-market trading, buoyed by social media discussions of the CEO's $9 million stock purchase amid a significant year-to-date decline.

12 aug. 2026, 23:06 UTC

Boston Scientific Corp shares are modestly higher in after-market trading. The stock remains significantly above its 20-day moving average.

11 aug. 2026, 23:41 UTC

Boston Scientific Corp shares are lower in after-market trading, showing unusual volatility and reflecting a broader trend of weakness since Tuesday's close.

10 aug. 2026, 23:06 UTC

Boston Scientific shares are trading higher in after-market hours, amid mixed market sentiment influenced by geopolitical tensions, particularly concerning the Strait of Hormuz.

8 aug. 2026, 00:01 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting gains since Friday's close and remaining above their 20-day moving average.

7 aug. 2026, 23:21 UTC

Boston Scientific shares are higher in after-market hours following a Labor Department report showing a decline in non-farm payroll employment, reducing interest rate hike expectations.

6 aug. 2026, 23:01 UTC

Boston Scientific Corp shares are higher during after-market hours, reflecting a generally strong performance backdrop amid resilient labor market data.

5 aug. 2026, 23:02 UTC

Social Media
News

Boston Scientific Corp shares rose in after-market trading following CEO Mahoney's purchase of 186,240 shares at an average price of $48.33.

4 aug. 2026, 19:36 UTC

News

Boston Scientific shares are higher, supported by strong organic revenue growth and rising free cash flow margin, despite recent economic data pressures.

3 aug. 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting positive momentum. Broader economic news shows increased growth in the manufacturing sector.

31 iul. 2026, 22:52 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting positive market sentiment from strong earnings by major tech companies.

30 iul. 2026, 23:51 UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

29 iul. 2026, 23:51 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting broader market gains. No specific news has been identified to explain the movement.

28 iul. 2026, 23:52 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting a steady increase since Tuesday's close despite broader market concerns, particularly in Asia.

27 iul. 2026, 23:02 UTC

News
Social Media

Boston Scientific plans a restructuring with pre-tax charges of $700 million to $800 million, leading shares lower in after-market hours.

25 iul. 2026, 00:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

24 iul. 2026, 23:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

22 iul. 2026, 20:06 UTC

Correlated Moves

Boston Scientific reported first-quarter adjusted EPS of $0.43, missing estimates. Shares are trading lower amid cautious market sentiment and Stryker's decline.

21 iul. 2026, 23:06 UTC

Boston Scientific Corp shares are higher in after-hours trading, reflecting a modest uptick following Tuesday's close. The stock remains below its 20-day moving average.

20 iul. 2026, 23:01 UTC

Boston Scientific shares are higher in after-market trading, reflecting notable strength since Monday's close, despite no specific news driving the movement.

Comparație

Modificare preț

Boston Scientific Corp. Așteptări

Obiectiv de preț

By TipRanks

20.41% sus

Prognoză pe 12 luni

Medie 62.41 USD  20.41%

Maxim 89 USD

Minim 50 USD

În baza a 24 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBoston Scientific Corp. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

24 ratings

21

Cumpărare

3

Păstrare

0

Vânzare

Sentiment

By Acuity

144 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat